Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 186

1.

Efficient long-term amplification of hepatitis B virus isolates after infection of slow proliferating HepG2-NTCP cells.

König A, Yang J, Jo E, Park KHP, Kim H, Than TT, Song X, Qi X, Dai X, Park S, Shum D, Ryu WS, Kim JH, Yoon SK, Park JY, Ahn SH, Han KH, Gerlich WH, Windisch MP.

J Hepatol. 2019 Aug;71(2):289-300. doi: 10.1016/j.jhep.2019.04.010. Epub 2019 May 8.

2.

Quantification of large and middle proteins of hepatitis B virus surface antigen (HBsAg) as a novel tool for the identification of inactive HBV carriers.

Pfefferkorn M, Böhm S, Schott T, Deichsel D, Bremer CM, Schröder K, Gerlich WH, Glebe D, Berg T, van Bömmel F.

Gut. 2018 Nov;67(11):2045-2053. doi: 10.1136/gutjnl-2017-313811. Epub 2017 Sep 26.

PMID:
28951526
3.

Do we need better hepatitis B vaccines?

Gerlich WH.

Indian J Med Res. 2017 Apr;145(4):414-419. doi: 10.4103/ijmr.IJMR_1852_16. No abstract available.

4.

Development of an Allergy Immunotherapy Leads to a New Type of Hepatitis B Vaccine.

Gerlich WH, Glebe D.

EBioMedicine. 2016 Sep;11:5-6. doi: 10.1016/j.ebiom.2016.07.032. Epub 2016 Jul 27. No abstract available.

5.

International collaborative study on the 3rd WHO International Standard for hepatitis B surface antigen.

Wilkinson DE, Seiz PL, Schüttler CG, Gerlich WH, Glebe D, Scheiblauer H, Nick S, Chudy M, Dougall T, Stone L, Heath AB; Collaborative Study Group.

J Clin Virol. 2016 Sep;82:173-180. doi: 10.1016/j.jcv.2016.06.003. Epub 2016 Jun 6.

6.

Characterization of the 3rd International Standard for hepatitis B virus surface antigen (HBsAg).

Seiz PL, Mohr C, Wilkinson DE, Ziebuhr J, Schüttler CG, Gerlich WH, Glebe D.

J Clin Virol. 2016 Sep;82:166-172. doi: 10.1016/j.jcv.2016.05.009. Epub 2016 Jun 3.

PMID:
27345250
7.

Studies of nosocomial outbreaks of hepatitis B in nursing homes in Germany suggest a major role of hepatitis B e antigen expression in disease severity and progression.

Seiz PL, Slanina H, Ziebuhr J, Gerlich WH, Glebe D, Schüttler CG.

Int J Med Microbiol. 2015 Oct;305(7):663-72. doi: 10.1016/j.ijmm.2015.08.016. Epub 2015 Aug 21.

PMID:
26338147
8.

Age-dependent decrease of anti-HBs titers and effect of booster doses using 2 different vaccines in Palestinian children vaccinated in early childhood.

Qawasmi M, Samuh M, Glebe D, Gerlich WH, Azzeh M.

Hum Vaccin Immunother. 2015;11(7):1717-24. doi: 10.1080/21645515.2015.1041687.

9.

Hepatitis B outbreak in a nursing home associated with reusable lancet devices for blood glucose monitoring, Northern Germany 2010.

Diercke M, Monazahian M, Petermann H, Gerlich WH, Schüttler CG, Wend U, Dehnert M, Dreesman J.

J Med Virol. 2015 Apr;87(4):583-8. doi: 10.1002/jmv.24104. Epub 2015 Jan 21.

PMID:
25611818
10.

Entecavir allows an unexpectedly high residual replication of HBV mutants resistant to lamivudine.

Geipel A, Seiz PL, Niekamp H, Neumann-Fraune M, Zhang K, Kaiser R, Protzer U, Gerlich WH, Glebe D; HOPE Consortium.

Antivir Ther. 2015;20(8):779-87. doi: 10.3851/IMP2928. Epub 2015 Jan 5.

PMID:
25560463
11.

Prophylactic vaccination against hepatitis B: achievements, challenges and perspectives.

Gerlich WH.

Med Microbiol Immunol. 2015 Feb;204(1):39-55. doi: 10.1007/s00430-014-0373-y. Epub 2014 Dec 19. Review.

PMID:
25523195
12.

More on hepatitis B virus rtI233V mutation and resistance to adefovir.

Geipel A, Glebe D, Gerlich WH.

N Engl J Med. 2014 Jul 31;371(5):483. doi: 10.1056/NEJMc1406607. No abstract available.

PMID:
25075851
13.
14.

Hepatitis B virus rtI233V mutation and resistance to adefovir.

Geipel A, Glebe D, Will H, Gerlich WH.

N Engl J Med. 2014 Apr 24;370(17):1667-8. doi: 10.1056/NEJMc1400292. No abstract available.

PMID:
24758635
15.

Bats carry pathogenic hepadnaviruses antigenically related to hepatitis B virus and capable of infecting human hepatocytes.

Drexler JF, Geipel A, König A, Corman VM, van Riel D, Leijten LM, Bremer CM, Rasche A, Cottontail VM, Maganga GD, Schlegel M, Müller MA, Adam A, Klose SM, Carneiro AJ, Stöcker A, Franke CR, Gloza-Rausch F, Geyer J, Annan A, Adu-Sarkodie Y, Oppong S, Binger T, Vallo P, Tschapka M, Ulrich RG, Gerlich WH, Leroy E, Kuiken T, Glebe D, Drosten C.

Proc Natl Acad Sci U S A. 2013 Oct 1;110(40):16151-6. doi: 10.1073/pnas.1308049110. Epub 2013 Sep 16.

16.

Medical virology of hepatitis B: how it began and where we are now.

Gerlich WH.

Virol J. 2013 Jul 20;10:239. doi: 10.1186/1743-422X-10-239. Review.

17.

Performance of hepatitis B surface antigen tests with the first WHO international hepatitis B virus genotype reference panel.

Chudy M, Scheiblauer H, Hanschmann KM, Kress J, Nick S, Wend U, Schüttler C, Nübling CM, Gerlich WH.

J Clin Virol. 2013 Sep;58(1):47-53. doi: 10.1016/j.jcv.2013.06.011. Epub 2013 Jul 3. Erratum in: J Clin Virol. 2013 Nov;58(3):598-9.

PMID:
23829967
18.

Posttranslational modifications and secretion efficiency of immunogenic hepatitis B virus L protein deletion variants.

Niedre-Otomere B, Bogdanova A, Bruvere R, Ose V, Gerlich WH, Pumpens P, Glebe D, Kozlovska T.

Virol J. 2013 Feb 25;10:63. doi: 10.1186/1743-422X-10-63.

19.

Infectivity of blood products from donors with occult hepatitis B virus infection.

Allain JP, Mihaljevic I, Gonzalez-Fraile MI, Gubbe K, Holm-Harritshøj L, Garcia JM, Brojer E, Erikstrup C, Saniewski M, Wernish L, Bianco L, Ullum H, Candotti D, Lelie N, Gerlich WH, Chudy M.

Transfusion. 2013 Jul;53(7):1405-15. doi: 10.1111/trf.12096. Epub 2013 Jan 30.

PMID:
23362802
20.

Reactivation of occult hepatitis B virus infection following cytotoxic lymphoma therapy in an anti-HBc negative patient.

Feeney SA, McCaughey C, Watt AP, Agnaf MR, McDougall N, Wend UC, Gerlich WH, Coyle PV.

J Med Virol. 2013 Apr;85(4):597-601. doi: 10.1002/jmv.23513. Epub 2013 Jan 28.

PMID:
23359331
21.

Recombinant Semliki Forest virus vectors encoding hepatitis B virus small surface and pre-S1 antigens induce broadly reactive neutralizing antibodies.

Niedre-Otomere B, Bogdanova A, Skrastina D, Zajakina A, Bruvere R, Ose V, Gerlich WH, Garoff H, Pumpens P, Glebe D, Kozlovska T.

J Viral Hepat. 2012 Sep;19(9):664-73. doi: 10.1111/j.1365-2893.2012.01594.x. Epub 2012 May 17.

PMID:
22863271
22.

Reactivation of hepatitis B virus with mutated hepatitis B surface antigen in a liver transplant recipient receiving a graft from an antibody to hepatitis B surface antigen- and antibody to hepatitis B core antigen-positive donor.

Blaich A, Manz M, Dumoulin A, Schüttler CG, Hirsch HH, Gerlich WH, Frei R.

Transfusion. 2012 Sep;52(9):1999-2006. doi: 10.1111/j.1537-2995.2011.03537.x. Epub 2012 Feb 8.

23.

[Prophylaxis, diagnosis and therapy of hepatitis B virus infection - the German guideline].

Cornberg M, Protzer U, Petersen J, Wedemeyer H, Berg T, Jilg W, Erhardt A, Wirth S, Sarrazin C, Dollinger MM, Schirmacher P, Dathe K, Kopp IB, Zeuzem S, Gerlich WH, Manns MP; AWMF.

Z Gastroenterol. 2011 Jul;49(7):871-930. doi: 10.1055/s-0031-1273462. Epub 2011 Jul 11. German. No abstract available.

PMID:
21748700
24.

Simple confirmatory assay for anti-HBc reactivity.

Huzly D, Nassal M, Vorreiter J, Falcone V, Neumann-Haefelin D, Gerlich WH, Panning M.

J Clin Virol. 2011 Aug;51(4):283-4. doi: 10.1016/j.jcv.2011.05.009. Epub 2011 May 31. No abstract available.

PMID:
21632284
25.

N-terminal myristoylation-dependent masking of neutralizing epitopes in the preS1 attachment site of hepatitis B virus.

Bremer CM, Sominskaya I, Skrastina D, Pumpens P, El Wahed AA, Beutling U, Frank R, Fritz HJ, Hunsmann G, Gerlich WH, Glebe D.

J Hepatol. 2011 Jul;55(1):29-37. doi: 10.1016/j.jhep.2010.10.019. Epub 2010 Nov 28.

PMID:
21145866
26.

European collaborative evaluation of the Enzygnost HBsAg 6.0 assay: performance on hepatitis B virus surface antigen variants.

Avellón A, Echevarría JM, Weber B, Weik M, Schobel U, Willems WR, Gerlich WH.

J Med Virol. 2011 Jan;83(1):95-100. doi: 10.1002/jmv.21943.

PMID:
21108344
27.

Occult hepatitis B virus infection: detection and significance.

Gerlich WH, Bremer C, Saniewski M, Schüttler CG, Wend UC, Willems WR, Glebe D.

Dig Dis. 2010;28(1):116-25. doi: 10.1159/000282074. Epub 2010 May 7. Review.

PMID:
20460899
28.

Tissue donation and virus safety: more nucleic acid amplification testing is needed.

Pruss A, Caspari G, Krüger DH, Blümel J, Nübling CM, Gürtler L, Gerlich WH.

Transpl Infect Dis. 2010 Oct;12(5):375-86. doi: 10.1111/j.1399-3062.2010.00505.x. Review.

PMID:
20412535
29.

Antigenic and physicochemical characterization of the 2nd International Standard for hepatitis B virus surface antigen (HBsAg).

Schüttler CG, Wend UC, Faupel FM, Lelie PN, Gerlich WH.

J Clin Virol. 2010 Mar;47(3):238-42. doi: 10.1016/j.jcv.2009.12.019. Epub 2010 Feb 1.

PMID:
20117963
30.

Re-evaluation of anti-HBc non-reactive serum samples from patients with persistent hepatitis B infection by immune precipitation with labelled HBV core antigen.

Kantelhardt VC, Schwarz A, Wend U, Schüttler CG, Willems WR, Trimoulet P, Fleury H, Gerlich WH, Kann M.

J Clin Virol. 2009 Oct;46(2):124-8. doi: 10.1016/j.jcv.2009.06.018. Epub 2009 Jul 24.

PMID:
19631583
31.

Transient occult hepatitis B virus infection in a blood donor with high viremia.

Bremer CM, Saniewski M, Wend UC, Torres P, Lelie N, Gerlich WH, Glebe D.

Transfusion. 2009 Aug;49(8):1621-9. doi: 10.1111/j.1537-2995.2009.02188.x.

PMID:
19413737
32.

Correlation of virus and host response markers with circulating immune complexes during acute and chronic woodchuck hepatitis virus infection.

Glebe D, Lorenz H, Gerlich WH, Butler SD, Tochkov IA, Tennant BC, Cote P, Menne S.

J Virol. 2009 Feb;83(4):1579-91. doi: 10.1128/JVI.01934-08. Epub 2008 Dec 3.

33.
34.

Statements from the Taormina expert meeting on occult hepatitis B virus infection.

Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, Craxì A, Donato F, Ferrari C, Gaeta GB, Gerlich WH, Levrero M, Locarnini S, Michalak T, Mondelli MU, Pawlotsky JM, Pollicino T, Prati D, Puoti M, Samuel D, Shouval D, Smedile A, Squadrito G, Trépo C, Villa E, Will H, Zanetti AR, Zoulim F.

J Hepatol. 2008 Oct;49(4):652-7. doi: 10.1016/j.jhep.2008.07.014. Epub 2008 Jul 31. No abstract available.

PMID:
18715666
35.

A new clade of hepatitis B virus subgenotype F1 from Peru with unusual properties.

von Meltzer M, Vásquez S, Sun J, Wendt UC, May A, Gerlich WH, Radtke M, Schaefer S.

Virus Genes. 2008 Oct;37(2):225-30. doi: 10.1007/s11262-008-0261-x. Epub 2008 Jul 23.

PMID:
18649130
36.

Combination of an antiviral drug and immunomodulation against hepadnaviral infection in the woodchuck model.

Lu M, Yao X, Xu Y, Lorenz H, Dahmen U, Chi H, Dirsch O, Kemper T, He L, Glebe D, Gerlich WH, Wen Y, Roggendorf M.

J Virol. 2008 Mar;82(5):2598-603. Epub 2007 Dec 26.

37.

Deficiencies in the standardization and sensitivity of diagnostic tests for hepatitis B virus.

Gerlich WH, Glebe D, Schüttler CG.

J Viral Hepat. 2007 Nov;14 Suppl 1:16-21. Review.

PMID:
17958638
38.

The serologic markers of hepatitis B virus infection--proper selection and standardized interpretation.

Caspari G, Gerlich WH.

Clin Lab. 2007;53(5-6):335-43, 391-400. Review. English, German. No abstract available.

PMID:
17605409
39.

The enigma of concurrent hepatitis B surface antigen (HBsAg) and antibodies to HBsAg.

Gerlich WH.

Clin Infect Dis. 2007 May 1;44(9):1170-2. Epub 2007 Mar 19. No abstract available.

PMID:
17407034
40.

Permanent loss of anti-HBc after reactivation of hepatitis B virus infection in an anti-HBs and anti-HBc-positive patient after allogeneic stem cell transplantation.

Gärtner BC, Jung W, Welsch C, Fischinger J, Schubert J, Zeuzem S, Mueller-Lantzsch N, Wend UC, Gerlich WH.

J Clin Virol. 2007 Feb;38(2):146-8. Epub 2006 Dec 19.

PMID:
17182277
41.

Reactivation of an occult hepatitis B virus escape mutant in an anti-HBs positive, anti-HBc negative lymphoma patient.

Awerkiew S, Däumer M, Reiser M, Wend UC, Pfister H, Kaiser R, Willems WR, Gerlich WH.

J Clin Virol. 2007 Jan;38(1):83-6. Epub 2006 Nov 28.

PMID:
17134939
42.

Genotype-dependent activation or repression of HBV enhancer II by transcription factor COUP-TF1.

Fischer SF, Schmidt K, Fiedler N, Glebe D, Schüttler C, Sun J, Gerlich WH, Repp R, Schaefer S.

World J Gastroenterol. 2006 Oct 7;12(37):6054-8.

43.

Differential effects on apoptosis induction in hepatocyte lines by stable expression of hepatitis B virus X protein.

Fiedler N, Quant E, Fink L, Sun J, Schuster R, Gerlich WH, Schaefer S.

World J Gastroenterol. 2006 Aug 7;12(29):4673-82.

44.
45.

Variant of hepatitis B virus with primary resistance to adefovir.

Schildgen O, Sirma H, Funk A, Olotu C, Wend UC, Hartmann H, Helm M, Rockstroh JK, Willems WR, Will H, Gerlich WH.

N Engl J Med. 2006 Apr 27;354(17):1807-12.

46.

Replacement of tenofovir with adefovir may result in reactivation of hepatitis B virus replication.

Schildgen O, Hartmann H, Gerlich WH.

Scand J Gastroenterol. 2006 Feb;41(2):245-6. No abstract available.

PMID:
16484132
47.

Outbreak of hepatitis B in a nursing home associated with capillary blood sampling.

Dreesman JM, Baillot A, Hamschmidt L, Monazahian M, Wend UC, Gerlich WH.

Epidemiol Infect. 2006 Oct;134(5):1102-13. Epub 2006 Jan 26.

48.

Mapping of the hepatitis B virus attachment site by use of infection-inhibiting preS1 lipopeptides and tupaia hepatocytes.

Glebe D, Urban S, Knoop EV, Cag N, Krass P, Grün S, Bulavaite A, Sasnauskas K, Gerlich WH.

Gastroenterology. 2005 Jul;129(1):234-45.

PMID:
16012950
49.

Methods for validation of hepatitis B virus inactivation.

Gerlich WH, Glebe D.

Dev Biol (Basel). 2004;118:113-22. No abstract available.

PMID:
15645680
50.

Diagnostic problems caused by HBsAg mutants-a consensus report of an expert meeting.

Gerlich WH.

Intervirology. 2004;47(6):310-3. No abstract available.

Supplemental Content

Loading ...
Support Center